All data are based on the daily closing price as of April 28, 2025
m
Medigen Vaccine Biologics
6547.TWO
1.54 USD
0.03
+1.99%
Overview
Last close
1.54 usd
Market cap
507.32M usd
52 week high
2.41 usd
52 week low
1.04 usd
Target price
3.14 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
27.1938
Price/Book Value
4.1882
Enterprise Value
448.17M usd
EV/Revenue
24.0206
EV/EBITDA
194.3198
Key financials
Revenue TTM
18.66M usd
Gross Profit TTM
12.21M usd
EBITDA TTM
-806007.39 usd
Earnings per Share
-0.01 usd
Dividend
N/A usd
Total assets
133.10M usd
Net debt
N/A usd
About
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses. The company also develops dengue vaccines, which has completed Phase II clinical trial to treat dengue; anti respiratory syncytial virus (RSV), which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19. Medigen Vaccine Biologics Corporation was incorporated in 2012 and is headquartered in Zhubei City, Taiwan. Medigen Vaccine Biologics Corporation is a subsidiary of Medigen Biotechnology Corp.